People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BlinkBio, Inc. | — | Biotechnology | Series B | $43.6M | $20.8M | 2019 |
| OS Therapies Inc | — | Biotechnology | Series A | $29.7M | $4.7M | 2022 |
Jutta Wanner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jutta Wanner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Colin Goddard | 2 | 5 |
| Geoff Smith | 1 | 6 |
| Mark Simon | 1 | 6 |
| Alan Lewis | 1 | 4 |
| Douglas Reed | 1 | 4 |
| Derek Small | 1 | 4 |
| James Schulz | 1 | 3 |
| Theodore F Search | 1 | 2 |
| Michael Gargano | 1 | 2 |
| Viren Mehta | 1 | 2 |
| Olivier R. Jarry | 1 | 2 |
| Kapil Dhingra | 1 | 2 |
| Joacim Borg | 1 | 1 |
| Theodore Search | 1 | 1 |
| Christopher Acevedo | 1 | 1 |
| John Ciccio | 1 | 1 |
| Robert Petit | 1 | 1 |
| Paul Romness | 1 | 1 |
| Maneesh Pingle | 1 | 1 |
| Paul A. Romness | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.